Trikafta (elexacaftor/tezacaftor/ivacaftor) - Vertex
Bridging the Gap in Eastern European Cystic Fibrosis Care: How Newborn Screening and Advanced CFTR Modulation Shape the Clinical Landscape in Western Romania. (PubMed, Children (Basel)) - Sep 27, 2026 - "Modulator therapy was received by 84.8% (76.1% elexacaftor/tezacaftor/ivacaftor)... CF characterization in western Romania demonstrates rapid modulator uptake and preserved lung function while highlighting persistent gaps in nutritional status, microbiological burden, and case detection relative to Western European populations. Longitudinal nationally representative studies are needed to confirm these findings." 
Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases
http://www.ncbi.nlm.nih.gov/pubmed/42794198
 
Alexandru Jurca; Alin Iuhas; Ariana Szilágyi; Claudia Maria Jurca; Cristian Sava
 
Sep 27, 2026
 
Prev Next